cilgavimab and tixagevimab (Evusheld) for COVID-19 - living meta-analysis of clinical studies

meta|evidence COVID-19

Living systematic review and meta-analysis

vs. potential COVID-19 treatments
vs. control
vs. placebo

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
root
secondary prevention

Studies
Mapping
Meta-analysis
Excluded 0

table network network 2

display ongoing demontrated benefit only

click on circles to display study description...

PROVENT, 2022 NCT04625725

cilgavimab and tixagevimab (Evusheld) (n=3460) vs. placebo (n=1737)

randomized controlled trial

Studied treatment

tixagevimab (AZD8895) and cilgavimab (AZD1061)
single dose (two consecutive intramuscular injections, one containing tixagevimab and the other containing cilgavimab) of 300 mg of AZD7442

Control treatment

placebo

Patients

COVID-19 prophylaxis (excluding children)

Method

double-blind

87 sites in the US, UK, Spain, France and Belgium

Remark

*Warning! The spread of new Sars-Cov2 variants is constantly evolving, this study was performed in a different viral context than today, its results should be interpreted accordingly.* preliminary results reported in a press release https://www.astrazeneca.com/media-centre/press-releases/2021/azd7442-prophylaxis-trial-met-primary-endpoint.html

powered by vis.js Network

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open